

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows.

In the Claims

- 1-11. (Cancelled)
12. (Currently amended) An isolated target mammalian adipose tissue cell transduced with a lentiviral vector, wherein the lentiviral vector is pseudotyped with at least part of an env protein, and wherein the at least part of the env protein is a VSV-G protein.
13. (Currently amended) A method of transducing a target mammalian adipose tissue cell comprising contacting the cell with a lentiviral vector, wherein the lentiviral vector is pseudotyped with at least part of an env protein, and wherein the at least part of the env protein is a VSV-G protein.
- 14-17. (Cancelled)
18. (Previously presented) The method of claim 13, wherein the lentiviral vector comprises at least one nucleotide sequence of interest (NOI).
19. (Previously presented) The method of claim 18, wherein the at least one NOI is a selection gene, a marker gene, a therapeutic gene, an antisense sequence or a cDNA library.
20. (Previously presented) The method of claim 18, wherein the at least one NOI blocks or inhibits the expression of a gene in the target adipose tissue cell.
21. (Previously presented) The method of claim 18, wherein at least part of the at least one NOI integrates into the genome of the target adipose tissue cell.
22. (Previously presented) The method of claim 18, wherein the at least one NOI encodes a protein of interest (POI).
23. (Original) The method of claim 22, wherein the POI is a therapeutic protein.
24. (Currently amended) A method of delivering an NOI to a target mammalian adipose tissue cell, comprising contacting the target adipose tissue cell with a lentiviral vector, wherein the lentiviral vector comprises an NOI, ~~and~~ wherein the lentiviral vector is pseudotyped with at least part of an env protein, and wherein the at least part of the env protein is a VSV-G protein.
- 25-30. (Cancelled)

31. (Previously presented) The method of claim 13, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.

32. (Cancelled)

33. (Cancelled)

34. (Previously presented) The method of claim 24, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.

35-39. (Cancelled)

40. (Previously presented) The target adipose tissue cell of claim 12, wherein the lentiviral vector is an HIV-based lentiviral vector or an EIAV-based lentiviral vector.